Waters Corporation 10-Q Summary: Quarter Ended March 31, 2002
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2002. Waters Corporation is the world's largest manufacturer and distributor of high performance liquid chromatography (HPLC) instruments, chromatography columns, consumables, and related services. Through subsidiaries Micromass Limited and TA Instruments, Inc., the Company also leads in mass spectrometry and thermal analysis. The three operating segments are aggregated into one reporting segment.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $200.3 million | $201.0 million |
| Gross Profit | $128.9 million | $127.7 million |
| Gross Margin | 64.3% | 63.5% |
| Operating Income | $44.2 million | $49.0 million |
| Net Income | $35.2 million | $38.4 million |
| Diluted EPS | $0.26 | $0.28 |
| Cash and Equivalents | $250.8 million | $89.2 million |
| Operating Cash Flow | $53.3 million | $24.6 million |
| Total Assets | $930.8 million | $886.9 million |
| Total Liabilities | $315.1 million | $305.2 million |
Debt and Liquidity: The Company holds $250.8 million in cash and cash equivalents. It maintains a $250.0 million unsecured credit facility. Notes payable were $1.6 million. The Company does not plan to pay dividends in the foreseeable future.
Material Changes vs. Prior Period
- Revenue: Net sales were relatively flat (-0.3%) compared to the prior year. Organic growth of 2% was offset by a 2% negative impact from currency translation (weakening Euro and Yen).
- Profitability: Net income decreased 8% to $35.2 million. Operating income declined 10% to $44.2 million.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 4% due to higher headcount. Research and development (R&D) expenses increased 11% to support new product development.
- Accounting Changes: The Company ceased goodwill amortization in Q1 2002 following the adoption of SFAS 142, reducing amortization expense by $0.8 million compared to the prior year.
- Cash Flow: Operating cash flow more than doubled to $53.3 million, driven by a decrease in accounts receivable and strong net income, despite increased inventory levels.
Guidance, Outlook, Risks, and Unusual Items
Patent Litigation (Critical Risk): A jury found that the Company's Quattro Ultima mass spectrometer infringes a patent held by Applera Corporation/MDS Inc., awarding $47.5 million in damages. The Company has accrued $76.1 million for patent litigation liabilities as of March 31, 2002, and recorded an additional $2.8 million charge in this quarter for interest and related costs. The Company has stopped U.S. shipments of the affected products and intends to appeal the verdict, arguing the patent is invalid due to inequitable conduct.
Outlook: Management believes current cash balances ($250.8 million) and the $250 million credit facility are sufficient to fund operations and cover potential adverse litigation outcomes. Sales growth slowed due to the litigation ruling and currency effects.
Investments: The Company invested $14.5 million in unaffiliated companies (including a $10 million equity investment in GeneProt) and $5.9 million in business acquisitions during the quarter.
Investor Verification Checklist
- Litigation Exposure: Verify the status of the appeal regarding the $47.5 million patent infringement verdict and the potential for an injunction on mass spectrometer sales.
- Currency Impact: Monitor the strength of the Euro and Yen, as currency translation significantly impacted reported sales growth.
- Inventory Levels: Review inventory growth ($8.9 million increase in cash used) to ensure it aligns with future sales expectations given the litigation constraints.
- Goodwill Impairment: Confirm the results of the transitional goodwill impairment test expected to be completed by June 30, 2002.
- GeneProt Alliance: Track the execution of the strategic alliance with GeneProt, including the shipment of mass spectrometry equipment planned for later in 2002.